Skip to main content

T-Cell Exhaustion Signatures Vary with Tumor Type and Are Severe in Glioblastoma.

Publication ,  Journal Article
Woroniecka, K; Chongsathidkiet, P; Rhodin, K; Kemeny, H; Dechant, C; Farber, SH; Elsamadicy, AA; Cui, X; Koyama, S; Jackson, C; Hansen, LJ ...
Published in: Clin Cancer Res
September 1, 2018

Purpose: T-cell dysfunction is a hallmark of glioblastoma (GBM). Although anergy and tolerance have been well characterized, T-cell exhaustion remains relatively unexplored. Exhaustion, characterized in part by the upregulation of multiple immune checkpoints, is a known contributor to failures amid immune checkpoint blockade, a strategy that has lacked success thus far in GBM. This study is among the first to examine, and credential as bona fide, exhaustion among T cells infiltrating human and murine GBM.Experimental Design: Tumor-infiltrating and peripheral blood lymphocytes (TILs and PBLs) were isolated from patients with GBM. Levels of exhaustion-associated inhibitory receptors and poststimulation levels of the cytokines IFNγ, TNFα, and IL2 were assessed by flow cytometry. T-cell receptor Vβ chain expansion was also assessed in TILs and PBLs. Similar analysis was extended to TILs isolated from intracranial and subcutaneous immunocompetent murine models of glioma, breast, lung, and melanoma cancers.Results: Our data reveal that GBM elicits a particularly severe T-cell exhaustion signature among infiltrating T cells characterized by: (1) prominent upregulation of multiple immune checkpoints; (2) stereotyped T-cell transcriptional programs matching classical virus-induced exhaustion; and (3) notable T-cell hyporesponsiveness in tumor-specific T cells. Exhaustion signatures differ predictably with tumor identity, but remain stable across manipulated tumor locations.Conclusions: Distinct cancers possess similarly distinct mechanisms for exhausting T cells. The poor TIL function and severe exhaustion observed in GBM highlight the need to better understand this tumor-imposed mode of T-cell dysfunction in order to formulate effective immunotherapeutic strategies targeting GBM. Clin Cancer Res; 24(17); 4175-86. ©2018 AACRSee related commentary by Jackson and Lim, p. 4059.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Clin Cancer Res

DOI

EISSN

1557-3265

Publication Date

September 1, 2018

Volume

24

Issue

17

Start / End Page

4175 / 4186

Location

United States

Related Subject Headings

  • Tumor Necrosis Factor-alpha
  • Tumor Microenvironment
  • T-Lymphocytes
  • Receptors, Antigen, T-Cell, alpha-beta
  • Oncology & Carcinogenesis
  • Middle Aged
  • Mice
  • Male
  • Lymphocytes, Tumor-Infiltrating
  • Interleukin-2
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Woroniecka, K., Chongsathidkiet, P., Rhodin, K., Kemeny, H., Dechant, C., Farber, S. H., … Fecci, P. E. (2018). T-Cell Exhaustion Signatures Vary with Tumor Type and Are Severe in Glioblastoma. Clin Cancer Res, 24(17), 4175–4186. https://doi.org/10.1158/1078-0432.CCR-17-1846
Woroniecka, Karolina, Pakawat Chongsathidkiet, Kristen Rhodin, Hanna Kemeny, Cosette Dechant, S Harrison Farber, Aladine A. Elsamadicy, et al. “T-Cell Exhaustion Signatures Vary with Tumor Type and Are Severe in Glioblastoma.Clin Cancer Res 24, no. 17 (September 1, 2018): 4175–86. https://doi.org/10.1158/1078-0432.CCR-17-1846.
Woroniecka K, Chongsathidkiet P, Rhodin K, Kemeny H, Dechant C, Farber SH, et al. T-Cell Exhaustion Signatures Vary with Tumor Type and Are Severe in Glioblastoma. Clin Cancer Res. 2018 Sep 1;24(17):4175–86.
Woroniecka, Karolina, et al. “T-Cell Exhaustion Signatures Vary with Tumor Type and Are Severe in Glioblastoma.Clin Cancer Res, vol. 24, no. 17, Sept. 2018, pp. 4175–86. Pubmed, doi:10.1158/1078-0432.CCR-17-1846.
Woroniecka K, Chongsathidkiet P, Rhodin K, Kemeny H, Dechant C, Farber SH, Elsamadicy AA, Cui X, Koyama S, Jackson C, Hansen LJ, Johanns TM, Sanchez-Perez L, Chandramohan V, Yu Y-RA, Bigner DD, Giles A, Healy P, Dranoff G, Weinhold KJ, Dunn GP, Fecci PE. T-Cell Exhaustion Signatures Vary with Tumor Type and Are Severe in Glioblastoma. Clin Cancer Res. 2018 Sep 1;24(17):4175–4186.

Published In

Clin Cancer Res

DOI

EISSN

1557-3265

Publication Date

September 1, 2018

Volume

24

Issue

17

Start / End Page

4175 / 4186

Location

United States

Related Subject Headings

  • Tumor Necrosis Factor-alpha
  • Tumor Microenvironment
  • T-Lymphocytes
  • Receptors, Antigen, T-Cell, alpha-beta
  • Oncology & Carcinogenesis
  • Middle Aged
  • Mice
  • Male
  • Lymphocytes, Tumor-Infiltrating
  • Interleukin-2